University of Louisville Journal of Respiratory Infections

EDITORIAL

COVID-19, Vaccination, and Heart Transplantation
Forest W. Arnold, DO MSc1∗
1

Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY, USA

∗ f.arnold@louisville.edu

Recommended Citation: Arnold FW. COVID-19, vaccination, and heart transplantation. Univ Louisville J Respir Infect 2022; 6(1):Article 14. doi:
10.55504/2473-2869.1248.

Operation Warp Speed was an
inter-agency partnership program involving the U.S. government and pharmaceutical companies to create and distribute a vaccine for COVID-19 as fast as safely possible. The pursuit is continuing as variants become
moving targets of vaccines much like influenza virus
and its need for an updated vaccine. The learning curve
to develop vaccines has been just as steep as for developing treatments and defining the best management
approach to the pandemic. Great progress has been
made. Consider the mortality difference noted with
the introduction of COVID-19 vaccines (Figure 1).[1]
See original article
by Belur et al.

Figure 1. Difference in incidence of mortality between vaccinated
and unvaccinated individuals, April 2021–February 2022. Data from
the Centers for Disease Control and Prevention, last updated April
15, 2022. Abbreviations: IR, incidence rate.

In this issue of the ULJRI, Belur et al. report a case of
COVID-19 in a heart transplant patient. As a case report, it represents how new knowledge is amassed by
disseminating and assimilating one study at a time.
Certainly, randomized control trials are the preferred
standard, but those are only funded after preliminary
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studies point toward a possible association of an intervention with an outcome.
For this topic of COVID-19, vaccination, and heart
transplantation, timing is everything. COVID-19 data
from the pandemic are relevant, but to benefit from
them, one must know when the case occurred since
management and treatment have been evolving and
vaccines have been phased into the population. Knowing at what time during the pandemic a patient was
treated is critical in interpreting what took place. This
particular case occurred in March 2021 when vaccines
were available, but prior to the approval of booster
doses. At that time, the Centers for Disease Control and
Prevention (CDC) guidelines recommended either two
mRNA (BNT 162b2 [Pfizer and BioNTech] or mRNA1273 [Moderna and the National Institutes of Health])
doses or one adenovirus (Ad26.COV2.S [Janssen Pharmaceuticals, Inc.]) dose. Since boosters had not yet
been recommended, the patient in the present case was
considered “fully vaccinated” at the time.[2]
The protection and efficacy provided by any vaccine
in an immunosuppressed person is always a question,
but the benefit of the COVID-19 vaccine, as with many
vaccines, is that if it does not prevent one from acquiring an infection, it may still prevent hospitalization or death from the infection. As one might imagine, solid organ transplant recipients require immunosuppressive regimens, with heart transplant recipients
typically requiring the most aggressive regimen.[3]
The length of treatment of a regimen is tied to the need
for immunosuppressives to prevent rejection of a transplanted organ and graft versus host disease balanced
with susceptibility to opportunistic infection or malignancy that may ensue with a compromised immune
system. Tolerance may develop to some degree, and it
may be possible to discontinue individual components
of a regimen, but lifetime suppression is usually necessary to prevent rejection after transplantation.
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The present case represents a heart transplant recipient
with a “breakthrough” infection as he had received two
mRNA vaccines prior to acquiring COVID-19. Belur et
al. review the immunosuppression of the patient and
discuss the efficacy—or lack thereof—of the vaccination he had received.
Qin et al. found that among 101 million adults in the US
who were vaccinated, 0.01% had a COVID-19 breakthrough infection while 0.83% of 18,215 transplant recipients had a breakthrough infection.[4] The mortality difference of breakthrough infections between the
general population and the transplanted was much
more significant at 0.00016% vs. 9.3%, respectively.
Outcomes among unvaccinated transplant recipients
were even worse with 5% acquiring COVID-19 [5] and
20% dying.[6] The patients in these studies were fully
vaccinated, and despite being a high-risk group, experienced decreased breakthrough infections and decreased mortality.
In a study of ∼48,000 solid organ recipients, mortality
from COVID-19 in those who did not receive a vaccine,
or who only received one dose, was 12.6% and 12.0%,
respectively, but for those who received two doses, the
mortality was only 7.7%.[7] The transplanted are obviously a significantly vulnerable group. Their lack of
humoral and cellular immunity makes them more susceptible, and they then struggle to clear infection once
they have it, but it appears that vaccination offers some
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protection for them.
Belur et al. chose to obtain IgG antibodies to assess the
vaccination status of their patient who had received
Pfizer’s BNT162b2 vaccine and had been on mycophenolate and tacrolimus. They checked a qualitative test
for antibodies to SARS-CoV-2, which was negative. A
cohort of heart transplant patients who had received
the Pfizer vaccine also did not respond well.[8] Among
77 heart transplant patients, only 14 had detectable
levels of IgG anti-receptor binding domain antibodies after a mean of 41 days from the second injection.
None of the patients who were on mycophenolate and
tacrolimus, like the patient in the present case report,
had antibodies detected. There has been at least one
call for a study to evaluate holding mycophenolate
mofetil in order to prevent immune paresis—a suboptimal humoral and cellular response to an antigen.[9]
However, just because antibodies are not detected, does
not mean that the vaccine is unsuccessful as demonstrated above with improved outcomes in spite of low
antibody responses.
Despite the outcome in the present case, physicians
should not be deterred from vaccinating their heart
transplant patients based on an anecdotal experience
of a poor outcome in a vaccinated patient. No doubt,
updated vaccines that adjust for variants will further
improve outcomes in all populations, especially heart
transplant recipients.
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